Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

22.81
-0.2900-1.26%
Post-market: 22.810.00000.00%19:30 EDT
Volume:471.46K
Turnover:10.76M
Market Cap:1.51B
PE:-7.34
High:24.23
Open:23.29
Low:22.40
Close:23.10
52wk High:30.99
52wk Low:10.30
Shares:66.17M
Float Shares:36.76M
Volume Ratio:0.96
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1097
EPS(LYR):-2.5230
ROE:-41.01%
ROA:-26.14%
PB:3.22
PE(LYR):-9.04

Loading ...

Analysts Are Bullish on Top NA Stocks: Veradermics, Incorporated (MANE), Bicara Therapeutics Inc. (BCAX)

TIPRANKS
·
Aug 12

Wedbush Adjusts PT on Bicara Therapeutics to $33 From $30, Keeps Outperform Rating

MT Newswires Live
·
Aug 11

Bicara Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Bicara Therapeutics Releases Corporate Deck Highlighting Ficerafusp Alfa EGFR-TGF-Β Program in HPV-Negative Head and Neck Cancer

Reuters
·
Aug 11

Bicara Therapeutics Appoints Operating Chief Cohlhepp as CEO in Leadership Shuffle

Dow Jones
·
Aug 11

Bicara Therapeutics Q2 Loss Widens

MT Newswires Live
·
Aug 11

Earnings Flash (BCAX) Bicara Therapeutics Posts Q2 Loss $0.82 a Share, vs. FactSet Est of $0.82 Loss

MT Newswires Live
·
Aug 11

Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) Estimate

Benzinga Earnings
·
Aug 11

Bicara Therapeutics - Appoints Ryan Cohlhepp as President & CEO Effective January 2027

THOMSON REUTERS
·
Aug 11

Bicara Therapeutics - Appoints Jenn Larson as CFO Effective August 12, 2026

THOMSON REUTERS
·
Aug 11

Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

THOMSON REUTERS
·
Aug 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 11

Bicara Therapeutics to Report Q2 Results, Provide Business Update in Conference Call

Reuters
·
Aug 04

Will New Oncology Veterans on Bicara Therapeutics' (BCAX) Board Reshape Its Late-Stage Strategy?

Simply Wall St.
·
Jul 30

Bicara Therapeutics Director Christy J. Oliger Files Initial Beneficial Ownership Statement

Reuters
·
Jul 30

Bicara Therapeutics reshapes board for commercialization push

TIPRANKS
·
Jul 28

Bicara Therapeutics Names Jeremy Bender, Christy Oliger to Board

Reuters
·
Jul 28

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

THOMSON REUTERS
·
Jul 28

Jeet Mukherjee Reiterates Buy on Bicara, Maintains $28 Price Target on Differentiated Ficera Profile and Upside Potential

TIPRANKS
·
Jul 28

Bicara CEO Claire Mazumdar Sells 10,000 Common Shares for $283,440

Reuters
·
Jul 15